Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 104

1.

Thromboxane A2 inhibition: therapeutic potential in bronchial asthma.

Dogné JM, de Leval X, Benoit P, Delarge J, Masereel B.

Am J Respir Med. 2002;1(1):11-7. Review.

PMID:
14720071
2.

Pharmacological evaluation of the novel thromboxane modulator BM-567 (II/II). Effects of BM-567 on osteogenic sarcoma-cell-induced platelet aggregation.

de Leval X, Benoit V, Delarge J, Julémont F, Masereel B, Pirotte B, Merville MP, David JL, Dogné JM.

Prostaglandins Leukot Essent Fatty Acids. 2003 Jan;68(1):55-9.

PMID:
12538091
3.

New pyridobenzodiazepine derivatives: modifications of the basic side chain differentially modulate binding to dopamine (D(4.2), D(2L)) and serotonin (5-HT(2A)) receptors.

Liégeois JF, Eyrolles L, Ellenbroek BA, Lejeune C, Carato P, Bruhwyler J, Géczy J, Damas J, Delarge J.

J Med Chem. 2002 Nov 7;45(23):5136-49.

PMID:
12408724
4.

New trends in dual 5-LOX/COX inhibition.

Leval Xd, Julemont F, Delarge J, Pirotte B, Dogne JM.

Curr Med Chem. 2002 May;9(9):941-62. Review.

PMID:
11966455
5.

Recent advances in antiplatelet agents.

Dogne JM, de Leval X, Benoit P, Delarge J, Masereel B, David JL.

Curr Med Chem. 2002 Mar;9(5):577-89. Review.

PMID:
11945125
6.

Synthesis and biological evaluation of aroylguanidines related to amiloride as inhibitors of the human platelet Na(+)/H(+) exchanger.

Laeckmann D, Rogister F, Dejardin JV, Prosperi-Meys C, Géczy J, Delarge J, Masereel B.

Bioorg Med Chem. 2002 Jun;10(6):1793-804.

PMID:
11937337
7.

Minimal effects of JL 13, a pyridobenzoxazepine derivative with an antipsychotic potential, on circulating prolactin levels in male rats.

Liégeois JF, Bruhwyler J, Hendrick JC, Delarge J, Legros JJ, Damas J.

Neurosci Lett. 2002 Feb 8;319(1):49-52.

PMID:
11814651
8.

The behavioral effects of acute and chronic JL 13, a putative antipsychotic, in Cebus non-human primates.

Casey DE, Bruhwyler J, Delarge J, Géczy J, Liégeois JF.

Psychopharmacology (Berl). 2001 Sep;157(3):228-35.

PMID:
11605077
9.

Novel inhibitors of the sodium-calcium exchanger: benzene ring analogues of N-guanidino substituted amiloride derivatives.

Rogister F, Laeckmann D, Plasman P, Van Eylen F, Ghyoot M, Maggetto C, Liégeois J, Géczy J, Herchuelz A, Delarge J, Masereel B.

Eur J Med Chem. 2001 Jul-Aug;36(7-8):597-614.

PMID:
11600230
10.

In vitro effects of aceclofenac and its metabolites on the production by chondrocytes of inflammatory mediators.

Henrotin Y, de Leval X, Mathy-Hartet M, Mouithys-Mickalad A, Deby-Dupont G, Dogné JM, Delarge J, Reginster JY.

Inflamm Res. 2001 Aug;50(8):391-9.

PMID:
11556519
11.

Activity of a novel dual thromboxane A(2)receptor antagonist and thromboxane synthase inhibitor (BM-573) on platelet function and isolated smooth muscles.

Rolin S, Dogné JM, Michaux C, Delarge J, Masereel B.

Prostaglandins Leukot Essent Fatty Acids. 2001 Aug;65(2):67-72.

PMID:
11545621
12.

Pharmacology of the thromboxane receptor antagonist and thromboxane synthase inhibitor BM-531.

Dogné JM, Rolin S, de Leval X, Benoit P, Neven P, Delarge J, Kolh P, Damas J, David JL, Masereel B.

Cardiovasc Drug Rev. 2001 Summer;19(2):87-96. Review.

PMID:
11484064
13.

Original 2-alkylamino-6-halogenoquinazolin-4(3H)-ones and K(ATP) channel activity.

Somers F, Ouedraogo R, Antoine MH, de Tullio P, Becker B, Fontaine J, Damas J, Dupont L, Rigo B, Delarge J, Lebrun P, Pirotte B.

J Med Chem. 2001 Aug 2;44(16):2575-85.

PMID:
11472211
14.

Evaluation of classical NSAIDs and COX-2 selective inhibitors on purified ovine enzymes and human whole blood.

de Leval X, Delarge J, Devel P, Neven P, Michaux C, Masereel B, Pirotte B, David JL, Henrotin Y, Dogne JM.

Prostaglandins Leukot Essent Fatty Acids. 2001 Apr-May;64(4-5):211-6.

PMID:
11418014
15.

Design, synthesis and biological evaluation of a sulfonylcyanoguanidine as thromboxane A2 receptor antagonist and thromboxane synthase inhibitor.

Dogné JM, Wouters J, Rolin S, Michaux C, Pochet L, Durant F, Delarge J, Masereel B.

J Pharm Pharmacol. 2001 May;53(5):669-80.

PMID:
11370706
16.

Structure determination and comparison of BM567, a sulfonylurea, with terbogrel, two compounds with dual action, thromboxane receptor antagonism and thromboxane synthase inhibition.

Michaux C, Rolin S, Dogné JM, Durant F, Masereel B, Delarge J, Wouters J.

Bioorg Med Chem Lett. 2001 Apr 23;11(8):1019-22.

PMID:
11327579
17.

Electrooxidation potential as a tool in the early screening for new safer clozapine-like analogues.

Mouithys-Mickalad A, Kauffmann JM, Petit C, Bruhwyler J, Liao Y, Wikström H, Damas J, Delarge J, Deby-Dupont G, Géczy J, Liégeois JF.

J Med Chem. 2001 Mar 1;44(5):769-76.

PMID:
11262087
18.

Isosterism among analogues of torasemide: conformational, electronic and lipophilic properties.

Wouters J, Michaux C, Durant F, Dogné JM, Delarge J, Masereel B.

Eur J Med Chem. 2000 Oct;35(10):923-9.

PMID:
11121618
19.

Therapeutic and chemical developments of cholecystokinin receptor ligands.

de Tullio P, Delarge J, Pirotte B.

Expert Opin Investig Drugs. 2000 Jan;9(1):129-46. Review.

PMID:
11060666
20.

Terbogrel, a dual-acting agent for thromboxane receptor antagonism and thromboxane synthase inhibition.

Michaux C, Norberg B, Dogné JM, Durant F, Masereel B, Delarge J, Wouters J.

Acta Crystallogr C. 2000 Oct;56 ( Pt 10):1265-6.

PMID:
11025320
21.

Recent advances in inducible cyclooxygenase (COX-2) inhibition.

de Leval X, Delarge J, Somers F, de Tullio P, Henrotin Y, Pirotte B, Dogné JM.

Curr Med Chem. 2000 Oct;7(10):1041-62. Review.

PMID:
10911017
22.

Effects of a novel non-carboxylic thromboxane A2 receptor antagonist (BM-531) derived from torasemide on platelet function.

Dogné JM, de Leval X, Neven P, Rolin S, Wauters J, David JL, Delarge J, Massereel B.

Prostaglandins Leukot Essent Fatty Acids. 2000 May;62(5):311-7.

PMID:
10883063
23.

New trends in thromboxane and prostacyclin modulators.

Dogné JM, de Leval X, Delarge J, David JL, Masereel B.

Curr Med Chem. 2000 Jun;7(6):609-28. Review.

PMID:
10702629
24.

Effects of JL 3, a putative antidepressant, on rat noradrenergic and serotonergic systems.

Liégeois J, Seutin V, Scuvée-Moreau J, Dresse A, Bruhwyler J, Géczy J, Delarge J, Damas J.

Eur J Pharmacol. 1999 Dec 15;386(2-3):211-6.

PMID:
10618472
25.

6-Substituted 2-oxo-2H-1-benzopyran-3-carboxylic acid as a core structure for specific inhibitors of human leukocyte elastase.

Doucet C, Pochet L, Thierry N, Pirotte B, Delarge J, Reboud-Ravaux M.

J Med Chem. 1999 Oct 7;42(20):4161-71.

PMID:
10514286
26.

Oxidation sensitivity may be a useful tool for the detection of the hematotoxic potential of newly developed molecules: application to antipsychotic drugs.

Liégeois JF, Bruhwyler J, Petit C, Damas J, Delarge J, Géczy J, Kauffmann JM, Lamy M, Meltzer H, Mouithys-Mickalad A.

Arch Biochem Biophys. 1999 Oct 1;370(1):126-37.

PMID:
10496986
27.

Preparation and pharmacological evaluation of the R- and S-enantiomers of 3-(2-butylamino)-4H- and 3-(3-methyl-2-butylamino)-4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxide, two tissue selective ATP-sensitive potassium channel openers.

Khelili S, de Tullio P, Lebrun P, Fillet M, Antoine MH, Ouedraogo R, Dupont L, Fontaine J, Felekidis A, Leclerc G, Delarge J, Pirotte B.

Bioorg Med Chem. 1999 Aug;7(8):1513-20.

PMID:
10482443
28.

Thromboxane A2 receptor antagonism in man and rat by a sulphonylcyanoguanidine (BM-144) and a sulphonylurea (BM-500).

Masereel B, Damas J, Fontaine J, Lembege M, Lacan F, Nuhrich A, Delarge J, Pochet L, Dogne JM.

J Pharm Pharmacol. 1999 Jun;51(6):695-701.

PMID:
10454046
29.

Effects of nimesulide and indometacin on COX-1 and COX-2: a comparative study.

de Leval X, Dogné JM, Neven P, Labasse A, Delarge J, Reginster JY, Henrotin Y.

J Pharm Belg. 1999 May-Jun;54(3):89-90.

PMID:
10431478
30.

BM 144: an original thromboxane A2 receptor antagonist derived from torasemide.

Dogné JM, Neven P, Damas J, Fontaine J, Rolin S, De Leval X, Delarge J, Masereel B.

J Pharm Belg. 1999 Mar-Apr;54(2):57-8.

PMID:
10380411
31.

Recent advances in the chemistry of cholecystokinin receptor ligands (agonists and antagonists).

de Tullio P, Delarge J, Pirotte B.

Curr Med Chem. 1999 Jun;6(6):433-55. Review.

PMID:
10213792
32.

Comparative study of pirlindole, a selective RIMA, and its two enantiomers using biochemical and behavioural techniques.

Bruhwyler J, Liégeois JF, Gérardy J, Damas J, Chleide E, Lejeune C, Decamp E, de Tullio P, Delarge J, Dresse A, Géczy J.

Behav Pharmacol. 1998 Dec;9(8):731-7.

PMID:
9890262
33.

Pyridothiadiazinedioxides structurally related to quinazolinones cholecystokinin/gastrin receptor ligands: synthesis and biological evaluation.

Pirotte B, de Tullio P, Podona T, Diouf O, Dewalque D, Neven P, Masereel B, Caignard P DH, Renard P, Delarge J.

Eur J Pharm Sci. 1998 Dec;7(1):29-40.

PMID:
9845775
34.

Synthesis and anticonvulsant activity of 2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives

Ucar H, Van derpoorten K, Cacciaguerra S, Spampinato S, Stables JP, Depovere P, Isa M, Masereel B, Delarge J, Poupaert JH.

J Med Chem. 1998 Jul 30;41(16):3102. No abstract available.

PMID:
9685250
36.

Dopamine D4 receptors: a new opportunity for research on schizophrenia.

Liégeois J, Eyrolles L, Bruhwyler J, Delarge J.

Curr Med Chem. 1998 Apr;5(2):77-100. Review.

PMID:
9481035
37.

Synthesis and anticonvulsant activity of 2(3H)-benzoxazolone and 2(3H)-benzothiazolone derivatives.

Ucar H, Van derpoorten K, Cacciaguerra S, Spampinato S, Stables JP, Depovere P, Isa M, Masereel B, Delarge J, Poupaert JH.

J Med Chem. 1998 Mar 26;41(7):1138-45. Erratum in: J Med Chem 1998 Jul 30;41(16):3102.

PMID:
9544213
38.

Effect of potassium channel openers on the firing rate of hippocampal pyramidal cells and A10 dopaminergic neurons in vitro.

Scuvée-Moreau J, Seutin V, Vrijens B, Pirotte B, De Tullio P, Massotte L, Albert A, Delarge J, Dresse A.

Arch Physiol Biochem. 1997 Sep;105(5):421-8.

PMID:
9439778
39.

JL13, a pyridobenzoxazepine compound with potential atypical antipsychotic activity: a review of its behavioural properties.

Bruhwyler J, Liégeois JF, Bergman J, Carey G, Goudie A, Taylor A, Meltzer H, Delarge J, Géczy J.

Pharmacol Res. 1997 Oct;36(4):255-64. Review.

PMID:
9425613
40.

JL 13, a potential successor to clozapine, is less sensitive to oxidative phenomena.

Liégeois JF, Mouithys-Mickalad A, Bruhwyler J, Delarge J, Petit C, Kauffmann JM, Lamy M.

Biochem Biophys Res Commun. 1997 Sep 8;238(1):252-5.

PMID:
9299488
41.

Pharmacomodulation of torasemide led to original diuretic, neuroprotective, anticonvulsant and antithrombotic drugs.

Masereel B, Dogné JM, Damas J, Nuhrich A, Varache-Lembège M, Fontaine J, Pochet L, Somers F, de Tullio P, Pirotte B, Delarge J.

J Pharm Belg. 1997 Jul-Aug;52(4):157-8.

PMID:
9316342
42.

Synthesis and biological evaluation of new 3-aralkylamino-2-aryl-2H-1, 2,4-pyridothiadiazine 1,1-dioxides as potential CCK-receptor ligands.

De Tullio P, Pirotte B, Neven P, Masereel B, Dewalque D, Diouf O, Podona T, Caignard D, Renard P, Delarge J.

J Pharm Pharmacol. 1997 May;49(5):463-71.

PMID:
9178178
43.
44.

Anticonvulsant activity of pyrid-3-yl-sulfonyl ureas and thioureas.

Masereel B, Lambert DM, Dogné JM, Poupaert JH, Delarge J.

Epilepsia. 1997 Mar;38(3):334-7.

45.

Pyridothiadiazines as potent inhibitors of glucose-induced insulin release.

Lebrun P, Antoine MH, Ouedraogo R, Herchuelz A, de Tullio P, Delarge J, Pirotte B.

Adv Exp Med Biol. 1997;426:145-8. No abstract available.

PMID:
9544267
46.

Dibenzoazepine analogues: the electrophysiological properties of JL3, a potential atypical antidepressant.

Liégeois JF, Scuvée-Moreau J, Giesbers I, Damas J, Bruhwyler J, Géczy J, Delarge J, Dresse A.

Eur J Pharmacol. 1996 Aug 22;310(1):9-12.

47.

Esters and amides of 6-(chloromethyl)-2-oxo-2H-1-benzopyran-3-carboxylic acid as inhibitors of alpha-chymotrypsin: significance of the "aromatic" nature of the novel ester-type coumarin for strong inhibitory activity.

Pochet L, Doucet C, Schynts M, Thierry N, Boggetto N, Pirotte B, Jiang KY, Masereel B, de Tullio P, Delarge J, Reboud-Ravaux M.

J Med Chem. 1996 Jun 21;39(13):2579-85.

PMID:
8691456
48.

Activation of ATP-dependent K+ channels and inhibition of insulin release: effect of BPDZ 62.

Lebrun P, Antoine MH, Ouedraogo R, Kane C, Dunne M, Hermann M, Herchuelz A, Masereel B, Delarge J, de Tullio P, Pirotte B.

J Pharmacol Exp Ther. 1996 Apr;277(1):156-62.

PMID:
8613913
49.

3-and 4-substituted 4H-pyrido[4,3-e]-1,2,4-thiadiazine 1,1-dioxides as potassium channel openers: synthesis, pharmacological evaluation, and structure-activity relationships.

de Tullio P, Pirotte B, Lebrun P, Fontaine J, Dupont L, Antoine MH, Ouedraogo R, Khelili S, Maggetto C, Masereel B, Diouf O, Podona T, Delarge J.

J Med Chem. 1996 Feb 16;39(4):937-48.

PMID:
8632417
50.

New dibenzazepine derivatives with disinhibitory and/or antidepressant potential: neurochemical and behavioural study in the open-field and forced swimming tests.

Bruhwyler J, Liégeois JF, Lejeune C, Rogister F, Delarge J, Géczy J.

Behav Pharmacol. 1995 Dec;6(8):830-838.

PMID:
11224387

Supplemental Content

Loading ...
Support Center